Building Cost Confidence into CRO Selection and Study Governance

Comparing CRO proposals based on the bottom-line alone can often lead to a false sense of certainty and confidence in your overall clinical trial budget.

What can make the price found in proposals so misleading for sponsors? The inherent variability of clinical research can lead to mid-study changes in scope, while differences in the assumptions underlying CRO costs can make proposals difficult to compare directly.

In this article, PharPoint’s Executive Director of Strategy Development Paul Johnson writes about how CRO selection, the importance of evaluating the assumptions that drive clinical trial costs, and how shared budget governance can support cost alignment throughout study execution.

–Test the Assumptions Behind Each Proposal

Sponsors must distinguish between a low-cost proposal and an overly-optimistic proposal that has been designed without consideration of potential study risks and realities.

A useful evaluation approach is to test the assumptions behind each proposal received, asking questions that dig into how assumptions were created and how likely they are to hold up in reality:

A proposal that appears less expensive at award may become more costly if it depends on rose-colored assumptions or limited project leadership, both of which can result in frequent downstream change orders that can significantly raise costs.

–Assess Operational Fit and Project Management Capability

While therapeutic familiarity is often important, it should be considered alongside the CRO’s ability to manage the operational realities of the proposed study. Sponsors should assess whether the CRO understands the specific execution challenges created by the protocol design, patient population, visit schedule, endpoint structure, geography, and vendor model.

In practice, experience with similar study designs may be more informative than broad indication experience alone. Sponsors should ask prospective CROs to describe comparable studies they have managed, the operational risks encountered, how those risks were addressed, and what lessons would apply to the proposed program.

The proposed project team should also be evaluated carefully. Sponsors should understand who will lead the study day to day, how decisions will be escalated, how milestones will be monitored, and how cross-functional issues will be resolved. In many cases, the quality of project leadership, communication cadence, and issue resolution processes will be more predictive of study performance than therapeutic credentials alone.

–Evaluate Forecasting and Feasibility Capabilities

Many study challenges originate long before the first participant is enrolled.

Strong feasibility assessments can help sponsors avoid unrealistic enrollment assumptions, overestimation of site performance, and underestimation of patient burden. CROs that employ data-driven feasibility methodologies and historical performance benchmarks should be able to develop realistic forecasts and identify potential bottlenecks before study startup.

Sponsors should ask prospective CROs:

• How are enrollment projections developed?
• What historical benchmarks support these assumptions?
• How are site performance forecasts validated?
• What contingency plans are built into recruitment models?
• What assumptions would most likely cause the timeline to change?

The quality of these answers often reveals more about future performance than the proposed timeline itself.

–Prioritize Transparency and Partnership

The most effective CRO relationships are built on transparency rather than optimism.

Sponsors should be cautious of partners that emphasize best-case timelines without acknowledging risk, as well as partners who come to the table with unusually low budgets without clearly articulated assumptions. In practice, every study carries uncertainty. Experienced CROs acknowledge this reality and proactively discuss potential challenges, alternative scenarios, and mitigation strategies.

Sponsors should look for CROs willing to serve as partners and advisors, not just vendors. The most valuable CROs are often those that challenge assumptions, identify tradeoffs, raise concerns early, and provide practical options when the plan needs to change.

– Establish Shared Ownership

Budget performance is often strongest when both sponsor and CRO accept joint responsibility for monitoring assumptions, evaluating emerging risks, and communicating potential financial impacts early.

Sponsors contribute oversight of development objectives, funding requirements, corporate priorities, and strategic decision-making. CROs contribute operational insight, execution data, forecasting expertise, and visibility into study performance trends. Combining these perspectives enables more informed and timely decisions than either party could make independently.

Successful governance models focus on collaboration rather than accountability for past variances. The objective is not to determine who was responsible for a budget deviation, but rather to understand why assumptions changed and what actions are needed moving forward.

– Review Assumptions Regularly

Mid-study changes in budget often originate when assumptions no longer reflect operational reality.

To avoid surprises, key assumptions should be reviewed routinely, including:

• Enrollment rates and recruitment timelines
• Screen failure rates
• Patient retention and withdrawal trends
• Site activation forecasts
• Monitoring requirements
• Data management workloads
• Vendor expenses
• Protocol amendment activity
• Geographic expansion requirements
• Study duration projections

Periodic review of these assumptions allows sponsors and CROs to identify risks while there is still time to mitigate their impact.

– Establish a Formal Financial Review Cadence

Budget governance should be incorporated into study management processes through a predefined review schedule.

Topics commonly addressed during financial review meetings include:

• Actual spend versus budget
• Forecasted costs to complete
• Changes in study assumptions
• Emerging operational risks
• Pending scope modifications
• Vendor performance and expenditures
• Contingency utilization
• Cash-flow projections

The specific cadence may vary by study size and complexity, but regular reviews help prevent small variances from developing into significant budget challenges.

– Create Clear Scope Change Processes

Due to the inherent unpredictability of clinical research, scope changes are a common reality – but should not leave sponsors blindsided. To manage this, the most effective governance frameworks define in advance how changes will be evaluated, documented, and approved.

Establishing clear decision pathways helps ensure that scope adjustments are evaluated consistently and transparently by both parties.

– Conduct Forward-Looking Reviews

Historical financial reporting is important, but governance discussions should emphasize future performance rather than past spending.

Forward-looking reviews should seek to answer questions such as:

• Are current assumptions still realistic?
• What events could materially affect cost or timeline?
• Are mitigation strategies needed?
• Is contingency funding adequate?
• Are there opportunities to improve efficiency without compromising quality?

This forward-looking approach enables sponsors to make informed decisions before challenges affect study milestones or capital planning.

– Make Transparency a Shared Expectation

The most effective sponsor-CRO relationships are characterized by early communication and open discussion of uncertainty.

Both parties should be encouraged to raise concerns regarding enrollment performance, resource needs, timeline assumptions, protocol complexity, or budget forecasts as soon as risks are identified. Addressing issues early is typically less disruptive and less costly than responding after problems have already affected study performance.

Conclusion

To have confidence that the budgets you receive from CROs are accurate, realistic, and flexible enough to accommodate the unexpected, transparency, collaboration, and shared ownership between a sponsor and CRO is necessary. Both parties have a role in identifying potential sources of budget variability, communicating openly if circumstances change, and working together to find solutions that align with the study’s financial and operational needs.

A trusted CRO partner should be willing to have those conversations early and often, helping sponsors navigate changes while keeping the broader budget and study objectives in view.